Bruker Corporation (BMV:BRKR)
Mexico · Delayed Price · Currency is MXN | Market Cap | 118.83B -1.8% |
| Revenue (ttm) | 62.35B +0.4% |
| Net Income | -656.20M |
| EPS | -4.32 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 19.73 |
| Dividend | 3.67 (0.52%) |
| Ex-Dividend Date | Mar 23, 2026 |
| Volume | n/a |
| Average Volume | 1,242 |
| Open | 705.00 |
| Previous Close | 705.00 |
| Day's Range | 705.00 - 705.00 |
| 52-Week Range | 615.00 - 1,085.50 |
| Beta | n/a |
| RSI | 41.56 |
| Earnings Date | May 6, 2026 |
About Bruker
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron par... [Read more]
News
Bruker Transcript: AGM 2026
The meeting confirmed a quorum, elected three directors through 2029, approved 2025 executive compensation, and ratified the appointment of independent auditors for 2026. Stockholders were invited to submit questions before adjournment.
Bruker price target raised to $45 from $40 at Stifel
Stifel analyst Daniel Arias raised the firm’s price target on Bruker (BRKR) to $45 from $40 and keeps a Hold rating on the shares.
Bruker price target raised to $45 from $43 at TD Cowen
TD Cowen raised the firm’s price target on Bruker (BRKR) to $45 from $43 and keeps a Hold rating on the shares. The firm updated its odel following Q1 results…
Bruker price target raised to $45 from $40 at UBS
UBS raised the firm’s price target on Bruker (BRKR) to $45 from $40 and keeps a Neutral rating on the shares.
Bruker price target raised to $53 from $45 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Bruker (BRKR) to $53 from $45 and keeps an Overweight rating on the shares.
Bruker price target raised to $44 from $40 at Citi
Citi raised the firm’s price target on Bruker (BRKR) to $44 from $40 and keeps a Neutral rating on the shares.
Bruker reports Q1 adjusted EPS 31c, consensus 23c
Reports Q1 revenue $823.4M, consensus $795.67M. Frank H. Laukien, Bruker’s (BRKR) President and CEO, commented: “While US academic demand, tariff and currency headwinds still pressured our first quart...
Bruker backs FY26 adjusted EPS view $2.10-$2.15, consensus $2.12
06:35 EDT Bruker (BRKR) backs FY26 adjusted EPS view $2.10-$2.15, consensus $2.12
Bruker Earnings Call Transcript: Q1 2026
Q1 2026 results exceeded expectations with strong bookings in AI-driven and security segments, despite U.S. academic and currency headwinds. Guidance for FY2026 is reaffirmed, with margin expansion and EPS growth driven by cost savings and innovation momentum.
Bruker Earnings release: Q1 2026
Bruker released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Bruker Slides: Q1 2026
Bruker has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Bruker Quarterly report: Q1 2026
Bruker has published its Q1 2026 quarterly earnings report on May 6, 2026.
Bruker Reports First Quarter 2026 Financial Results
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three months ended March 31, 2026. Frank H. Laukien, Bruker's President a...
Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2026 financial results before market opening on Wednesday, May 6, 2026...
Bruker to showcase updates from Bruker Spatial Biology at AACR meeting
Bruker (BRKR) Corporation announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Research Annual Meeting. At AACR, Bruker Spatial Biology will hi...
Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Resear...
Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PR...
Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management
MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequenc...
Bruker price target lowered to $45 from $50 at Barclays
Barclays lowered the firm’s price target on Bruker (BRKR) to $45 from $50 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and…
Bruker unveils NMR products, workflow solutions at ENC 2026
At the Experimental Nuclear Magnetic Resonance Conference, Bruker (BRKR) Corporation announced new NMR products and workflow solutions designed to expand performance, sensitivity, and automation acros...
Bruker Unveils New NMR Products and Workflow Solutions at ENC 2026
ASILOMAR, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--At the Experimental Nuclear Magnetic Resonance Conference (ENC), Bruker Corporation (Nasdaq: BRKR) today announced new NMR products and workflow solu...
Bruker Proxy statement: Proxy filing
Bruker filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Bruker Proxy statement: Proxy filing
Bruker filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Bruker invests in photothermal AFM-IR to advance semiconductor research
Bruker (BRKR) announced accelerated development of its photothermal AFM-IR spectroscopy capabilities to address research challenges facing the semiconductor industry as device architectures continue t...
Bruker Invests in Photothermal AFM-IR to Advance Semiconductor Research
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced accelerated development of its photothermal AFM-IR spectroscopy capabilities to address research ch...